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Abstract
Background: Rats emit 50 kHz ultrasonic vocalizations (USVs) in response to either natural or pharmacological pleasurable 
stimuli, and these USVs have emerged as a new behavioral measure for investigating the motivational properties of drugs. 
Earlier studies have indicated that activation of the dopaminergic system is critically involved in 50 kHz USV emissions. 
However, evidence also exists that non-dopaminergic neurotransmitters participate in this behavioral response.
Methods: To ascertain whether glutamate transmission plays a role in 50 kHz USV emissions stimulated by amphetamine, rats 
received five amphetamine (1–2 mg/kg, i.p.) administrations on alternate days in a test cage, either alone or combined with the 
glutamate N-methyl-D-aspartate receptor antagonist MK-801 (0.1–0.5 mg/kg, i.p.). Seven days after treatment discontinuation, rats 
were re-exposed to the test cage to assess drug conditioning, and afterwards received a drug challenge. USVs and locomotor activity 
were evaluated, along with immunofluorescence for Zif-268 in various brain regions and spontaneous alternation in a Y maze.
Results: Amphetamine-treated rats displayed higher 50 kHz USV emissions and locomotor activity than vehicle-treated rats, 
and emitted conditioned vocalizations on test cage re-exposure. Rats co-administered amphetamine and MK-801 displayed 
lower and dose-dependent 50 kHz USV emissions, but not lower locomotor activity, during repeated treatment and challenge, 
and scarce conditioned vocalization compared with amphetamine-treated rats. These effects were associated with lower 
levels of Zif-268 after amphetamine challenge and spontaneous alternation deficits.
Conclusions: These results indicate that glutamate transmission participates in the acute, long-term, and conditioned 
effects of amphetamine on 50 kHz USVs, possibly by influencing amphetamine-induced long-term neuronal changes and/or 
amphetamine-associated memories.
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Introduction
Solid experimental evidence indicates that the emission of 
ultrasonic vocalizations (USVs) may reflect changes in the 
emotional state of rats (Panksepp, 2005; Schwarting et al., 2007; 
Brudzynski, 2013; Simola, 2015). In particular, the so-called 
50 kHz USVs, which are contained within the 35–80 kHz fre-
quency range (Brudzynski, 2013), are thought to indicate posi-
tive affective states, since rats emit these vocalizations in 
response to or anticipation of pleasurable stimuli, such as 
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mating, heterospecific play with familiar humans (or “tickling”), 
and non-aggressive homospecific social encounters (Burgdorf 
et al., 2008, 2011). Interestingly, drugs of abuse can affect 50 kHz 
USV emissions (Wintink and Brudzynski, 2001; Mu et al., 2009; 
Simola et al., 2014); therefore, 50 kHz USVs are increasingly being 
used to study the motivational properties of drugs (Wright et al., 
2012a; Mahler et al., 2013; Barker et al., 2014; Taracha et al., 2014).
Earlier studies have demonstrated that activation of dopa-
mine receptors, particularly in the shell of the nucleus accum-
bens (NAc), is critically involved in the emission of 50 kHz USVs 
by rats (Thompson et al., 2006; Burgdorf et al., 2011). This find-
ing agrees with the results showing that drugs with marked 
dopaminomimetic properties robustly stimulate 50 kHz USV 
emissions (Wintink and Brudzynski, 2001; Mu et  al., 2009), 
while drugs devoid of these properties do not (Simola et  al., 
2010, 2014). However, evidence also exists showing that neu-
rotransmitters other than dopamine influence 50 kHz USVs. 
Emission of 50 kHz USVs by naïve rats has been observed 
after the intracerebral infusion of glutamate, as well as fol-
lowing the antagonism of either the κ-opioid or the seroto-
nin 5HT2C receptors (Fu and Brudzynski, 1994; Hamed et  al., 
2015; Wöhr et  al., 2015). Moreover, activation of either the α1 
or α2 noradrenaline receptors, or of the 5HT2C serotonin recep-
tors attenuates the emission of 50 kHz USVs stimulated by 
amphetamine (Wright et  al., 2012b; Wöhr et  al., 2015). These 
latter results are particularly relevant, since amphetamine is 
the prototype of drugs that stimulate 50 kHz USV emissions 
(Wright et al., 2012b). Moreover, recent studies have suggested 
that long-term changes in amphetamine’s effects on 50 kHz 
USVs may reflect modifications in the motivational proper-
ties of this drug with repeated experience (Ahrens et al., 2009; 
Simola and Morelli, 2015). Therefore, elucidating the role of 
different neurotransmitters in the effects of amphetamine on 
50 kHz USVs may help to develop new experimental models for 
studying the addictive properties of this drug. Amphetamine 
acts by stimulating the release of monoamines and glutamate 
in various brain regions (Shoblock et al., 2003; Iversen, 2008), 
and glutamate is involved in amphetamine’s addictive prop-
erties (Kalivas, 2007). However, while the role of monoamines 
in amphetamine’s effects on 50 kHz USVs has been described 
(Wright et al., 2012b, 2013; Wöhr et al., 2015), the role of gluta-
mate is unknown.
To address this issue, this study evaluated the influence of 
N-methyl-D-aspartate (NMDA) glutamate receptor antagonism 
on the acute, long-term, and conditioned effects of ampheta-
mine on 50 kHz USVs. To further clarify the importance of the 
results of this study, development of locomotor sensitization 
was also evaluated, to obtain an additional behavioral corre-
late of changes in amphetamine motivational properties with 
repeated experience (see Robinson and Berridge, 2001). This 
study specifically evaluated the involvement of NMDA recep-
tors in the effects of amphetamine on 50 kHz USVs, since these 
receptors are those most involved in the modulatory effects of 
glutamate transmission on amphetamine-induced behavio-
ral sensitization (Vanderschuren and Kalivas, 2000). Moreover, 
MK-801 was used to antagonize NMDA receptors, since this 
drug counteracts amphetamine-induced sensitization (Karler 
et  al., 1989; Wolf and Khansa, 1991). Finally, to investigate the 
mechanisms by which NMDA receptor antagonism influences 
amphetamine-stimulated 50 kHz USVs, this study evaluated the 
expression of the protein Zif-268 (an index of neuronal activa-
tion) in the NAc shell and core, dorsolateral striatum (DLS), and 
medial prefrontal cortex (mPFC), as well as rats’ spontaneous 
alternation in a Y maze as a measure of cognitive performance.
Methods
Subjects
Male Sprague–Dawley rats (Harlan) weighing 275–300 g were 
used. Rats (4 or 5 per cage) were housed in standard polycar-
bonate cages with sawdust bedding, and maintained on a 12-h 
light/dark cycle (lights on at 08:00). Food and water were freely 
available, except during the experiments, which were performed 
from 10:00 to 16:00.
All experiments were conducted in accordance with 
the guidelines for animal experimentation of the EU direc-
tives (2010/63/EU; L.276; 22/09/2010), and with the guidelines 
approved by the Ethical Committee of the University of Cagliari. 
Efforts were made to minimize animal discomfort and reduce 
the number of animals used.
Drugs
D-Amphetamine (sulfate) and MK-801 {dizocilpine, (5S,10R)-(+)-
5-methyl-10,11-dihydro5H-dibenzo[a,d]cyclohepten-5,10-imine 
apomorphine hydrogen maleate}, both obtained from Sigma–
Aldrich, were dissolved in distilled water and administered 
intraperitoneally (i.p.), in a 3 ml/kg (amphetamine) or 1 ml/kg 
(MK-801) volume. Drug doses were based on our previous stud-
ies on amphetamine-stimulated 50 kHz USVs (Simola et  al., 
2014; Simola and Morelli, 2015), and on our preliminary experi-
ments on the effects of MK-801 on 50 kHz USV emissions dur-
ing non-aggressive social interactions (data not shown). Doses 
of MK-801 refer to the maleate salt. MK-801 was administered 
15 min before behavioral evaluation at the doses of 0.1, 0.2, or 
0.5 mg/kg (i.p.). Amphetamine was administered immediately 
before behavioral evaluation at the doses of 1 or 2 mg/kg (i.p.).
Experimental Procedure
Experiments were designed according to Simola et al. (2014), and 
consisted of six phases: (1) test cage habituation; (2) acute vehi-
cle administration in the test cage, to quantify basal USVs; (3) 
repeated drug administration (×5) in the test cage every other 
day; (4) drug withdrawal in the home-cage; (5) re-exposure to 
the test cage, immediately followed by drug challenge; and (6) 
evaluation of rats’ performance in a Y maze.
USVs and locomotor activity were evaluated throughout 
phases 1–5. Rats were randomly assigned to their experimental 
group and were used only once. Rats treated with distilled water 
only (vehicle, i.p.) served as controls. Each experimental group 
included at least 7 rats (see figure legends for exact numbers). 
Figure 1 reports the detailed experimental plan.
Recording of USVs and Locomotor Activity
Experiments were performed in a quiet room. USV recordings 
were performed according to Simola et al. (2012). Briefly, each rat 
was placed alone in a Plexiglas cylinder (diameter, 25 cm; height, 
30 cm) topped with a lid equipped with an ultrasonic microphone 
(CM16/CMPA, Avisoft) and connected to an ultrasound-recording 
device (UltraSoundGate 116 Hb, Avisoft). During recordings, con-
stant gain was always maintained. Figure 2 shows examples of 
50 kHz USVs recorded during this study. USVs were recorded 
after drug or vehicle administration for 30 min, starting immedi-
ately after rats’ placement in the test cage. USVs emitted on test 
cage re-exposure were recorded for 10 min, starting immediately 
after re-exposure (Figure 1). The recording times were selected 
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as reported in Simola and Morelli (2015). Locomotor activity was 
recorded simultaneously with USVs by means of automated 
counters (Opto-Varimex; Columbus Instruments) equipped with 
a horizontal infrared beam emitter-detector system. The system 
was placed outside the cylinder, and oriented in order to project 
the infrared beams parallel to the floor of the cylinder.
Spontaneous Alternation
Spontaneous alternation behavior in a Y maze is widely used as 
a tool to evaluate the sensory/attentional and cognitive func-
tions (e.g. spatial working memory) of rodents and the amnesic 
effect of drugs (reviewed in Hughes, 2004). In the present study, 
spontaneous alternation was evaluated after completion of 
repeated drug treatment at the time points reported in Figure 1. 
To minimize the influence of previous drug treatment, sponta-
neous alternation was firstly evaluated in drug-free conditions 
(day 23)  to obtain a baseline value. Seven days later (day 30), 
spontaneous alternation was evaluated after acute pharmaco-
logical treatment which consisted of either: (i) MK-801 (0.1, 0.2, 
0.5 mg/kg, i.p.); (ii) amphetamine (1 mg/kg, i.p.); or (iii) ampheta-
mine (1 mg/kg, i.p.) in combination with MK-801 (0.1, 0.2 mg/kg, 
i.p.). On day 30, each rat received a pharmacological treatment 
different from the one it received in days 1–16.
The Y maze used was made of black PVC and had three equal-
sized symmetrical arms (named A, B, and C; length 50 cm, width 
20 cm, height 35 cm) converging onto a central triangular area. 
The maze was thoroughly cleaned with odorless soapy water 
and dried between each trial to remove olfactory cues. The test 
was performed by individually placing each rat in the central 
area and leaving it free to explore the maze for 8 min. Rats were 
videotaped, and alternation was subsequently calculated based 
on the sequence of arm entries. An arm entry was scored when 
a rat had all its four paws inside a specific arm. Alternation is 
defined as successive entries to the three arms on overlapping 
triplet sets in which three different arms are entered. For exam-
ple, a sequence of arm entries such as ABCBAB corresponds to 
two alternations: ABC and CBA. Spontaneous alternation was 
then expressed as a percentage obtained by dividing the num-
ber of alternations by the total number of triplets, which cor-
responds to the number of arm entries minus two (see Hughes, 
2004 for further details).
Immunofluorescence
Immunofluorescence experiments were performed to inves-
tigate the modifications in the levels of the protein Zif-268 in 
brain areas related to the emission of 50 kHz USVs and the moti-
vational properties of drugs of abuse. In the brain, the mRNA 
encoding for the early gene zif-268 is constitutively expressed 
in areas such as the striatum and the cortex (Schlingensiepen 
et  al., 1991). Moreover, zif-268 can be rapidly and transiently 
induced by a variety of pharmacological and physiological stim-
uli (Beckmann and Wilce, 1997), making this gene and its pro-
tein useful and sensitive markers in the evaluation of neuronal 
activity and its modifications.
Seven days after repeated treatment discontinuation, a sub-
set of rats were firstly re-exposed to the test cage in drug-free 
conditions for 10 min, and then challenged with either one of: 
(i) vehicle (i.p.); (ii) amphetamine (1 mg/kg, i.p.); or (iii) MK-801 
(0.2 mg/kg, i.p.). Experimental groups were composed as: (1) rats 
pretreated with vehicle and challenged with vehicle (VEH/VEH 
Figure 1. Experimental plan. Rats were habituated (15 min, twice a day) to the test cage for 2 days (H), then received an acute administration of vehicle (V) to evaluate 
basal emission of 50 kHz ultrasonic vocalizations (USVs). Starting from the day after vehicle administration, rats underwent repeated drug treatment on alternate days 
in the test cage (D). Recording of 50 kHz USVs was performed after each vehicle (vUSVs) or drug (dUSVs) administration in the test cage, re-exposure to the test cage 
(tcUSVs), or drug challenge administered immediately after test cage re-exposure (cUSVs), at the time points indicated. Rats’ locomotor activity (loc) was also recorded 
at the time points indicated. Finally, rats’ spontaneous alternation in a Y maze was evaluated after the completion of repeated drug treatment at the time points indi-
cated. C, drug challenge in the test cage; R, re-exposure to the test cage; SA1, spontaneous alternation evaluated in drug-free conditions; SA2, spontaneous alternation 
evaluated after acute pharmacological treatment.
Figure 2. Example of sonograms of 50 kHz ultrasonic vocalizations (USVs). USVs reported are examples of independent vocalizations emitted by different rats.
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group); (2) rats pretreated with MK-801 (0.2 mg/kg, i.p) and chal-
lenged with MK-801 (MK-801/MK-801 group); (3) rats pretreated 
with amphetamine (1 mg/kg, i.p.) and challenged with ampheta-
mine (AMPH/AMPH group); and (4) rats pretreated with amphet-
amine (1 mg/kg, i.p.) in combination with MK-801 (0.2 mg/kg, 
i.p) and challenged with amphetamine (AMPH + MK-801/AMPH 
group).
Each experimental group included 6 rats.
Ninety minutes after the challenge, rats were anesthetized 
with chloral hydrate and transcardially perfused with 0.9% NaCl 
followed by 4% paraformaldehyde in 0.1 M phosphate buffer (PB; 
pH = 7.4). Brains were postfixed overnight in the same solution 
(4°C) and coronally cut on a vibratome (40 μm) 2 days later. For 
each rat, four coronal sections were collected from 2.70 mm to 
2.20 mm (mPFC) and from 1.70 mm to 0.20 mm (DLS and NAc 
shell and core) relative to bregma, according to the rat brain 
atlas of Paxinos and Watson (1998).
Free-floating sections were rinsed in 0.1 M PB, blocked in 
a solution containing 3% normal goat serum and 0.3% Triton 
X-100 in 0.1 M PB at room temperature for 1 h, and incubated 
at 4°C in the same solution with the primary antibody for 2 
nights. A  purified rabbit polyclonal antibody against Zif-268 
(1:1000, Santa Cruz Biotechnology) was used. AlexaFluor 
594-labeled goat anti-rabbit immunoglobulin G (IgG) (1:400, 
Jackson ImmunoResearch) was used as secondary antibody. 
The Alexa Fluor 594 secondary antibody has a maximal light 
absorption around 591 nm, which allows its use for immu-
nofluorescence detection in the deep-red region of the vis-
ible spectrum. After incubation, sections were rinsed and 
mounted immediately onto glass slides coated with gelatin in 
Mowiol mounting medium.
Statistical Analysis
USV recordings were converted into spectrograms using the 
software SASLab Pro 4.52 (Avisoft) with the following settings: 
512 FFT-length, Hamming window, and 75% overlap frame set-
up. After visual inspection and manual cleaning of all signals 
that could not be univocally classified as vocalizations (see 
Simola et al., 2012), the number of 50 kHz USVs was automati-
cally calculated by SASLab Pro 4.52.
USV data collected in this study showed non-parametric dis-
tribution, and were square-root transformed before analyses. 
Figures report raw data for clarity. Means ± standard errors of 
the mean of the number of 50 kHz USVs and locomotor activity 
counts were calculated, and only data collected on days 0, 1, 5, 9, 
and 16 were analyzed by means of t-tests or analyses of variance 
(ANOVA). Baseline emissions of USVs and locomotor activity 
recorded after acute vehicle (day 0) revealed no significant group 
differences (data not shown). Three rats emitted 22 kHz USVs, 
which indicate negative affective states (Brudzynski, 2013), fol-
lowing pharmacological treatment, and were excluded from the 
analyses to avoid any possible influence of aversive effects of 
drugs on the results observed.
For repeated drug treatment, a two-factor ANOVA (treat-
ment × administration day) was used. For test cage re-exposure 
in the drug-free conditions and drug challenge, a one-factor 
ANOVA (treatment) was used. A  t-test was employed to ver-
ify the presence of significant differences between challenge 
with MK-801 and first administration of MK-801, as well as 
between challenge with amphetamine and first administra-
tion of amphetamine. Spontaneous alternation performed on 
days 23 and 30 was analyzed by means of a one-factor ANOVA 
(condition).
Stained brain sections were analyzed at ×20 magnification 
using an Axio Scope A1 light microscope (Zeiss) connected with 
a digital camera (1.4 MPixels, Infinity 3-1, Lumenera). The images 
obtained were processed using the Image J analysis software (US 
National Institutes of Health). Nuclei positive for Zif-268 were 
then identified for each slice and counted with the manual 
particle counting option of Image J. For each level of each brain 
area considered, the obtained value was first normalized with 
respect to the VEH/VEH group, then values from different lev-
els were averaged. Data were analyzed by means of a one-factor 
ANOVA (treatment).
Significance was set at p < 0.05 for each analysis, and ANOVA 
analyses were followed by Tukey’s post-hoc test, when appropri-
ate. Statistical analysis was performed with Statistica (StatSoft) 
and with Prism (GraphPad) for Windows.
Results
Emission of 50 kHz USVs and Locomotor Activity 
During Repeated Drug Treatment and Challenge
MK-801 
Emission of 50 kHz USVs by rats repeatedly treated with MK-801 
significantly differed from that of vehicle-treated rats. Two-way 
ANOVA revealed effects of treatment (F3,36 = 7.12, p = 0.0007) and 
treatment × time interaction (F6,72  =  2.20, p  =  0.0006). Tukey’s 
test showed that rats treated with each MK-801 dose vocal-
ized less than vehicle-treated rats, although rats treated with 
MK-801 (0.1 mg/kg) developed tolerance to this effect (Figure 3A, 
Supplementary Table S1).
Locomotor activity of rats repeatedly treated with MK-801 
significantly differed from that of vehicle-treated rats. Two-way 
ANOVA revealed effects of treatment (F3,36  =  80.33, p  =  0.0001), 
time (F2,72  =  5.76, p  =  0.005), and treatment × time interaction 
(F6,72 = 5.96, p = 0.0004). Tukey’s test showed that rats treated with 
MK-801 (0.5 mg/kg) exhibited higher locomotor activity than 
vehicle-treated rats at every time point considered (Figure  3B, 
Supplementary Table S1).
The MK-801 challenge influenced vocalization in a fashion 
significantly different from the vehicle challenge. One-way 
ANOVA revealed effect of treatment (F3,36  =  14.27, p  =  0.0001), 
and Tukey’s test showed that rats challenged with MK-801 
(0.1–0.5 mg/kg) vocalized less than vehicle-challenged rats. 
Moreover, t-test comparisons revealed that vocalization stimu-
lated by MK-801 challenge was lower than that elicited by the 
first MK-801 administration for every dose tested (0.1 mg/kg: 
t = 4.510, df = 16, p = 0.0004; 0.2 mg/kg: t = 3.42, df = 20, p = 0.003; 
0.5 mg/kg: t = 2.94, df = 14, p = 0.03; Figure 3A, Supplementary 
Table S1).
The MK-801 challenge stimulated locomotor activity in 
a fashion significantly different from the vehicle challenge, 
as shown by one-way ANOVA (F3,36 = 14.78, p = 0.0001). Tukey’s 
test showed higher locomotor activity in rats challenged with 
MK-801 (0.5 mg/kg) than in vehicle-challenged rats (Figure  3B, 
Table 1).
Amphetamine and Amphetamine + MK-801
Amphetamine (1 mg/kg)
Emission of 50 kHz USVs by rats repeatedly treated with 
amphetamine (1 mg/kg) significantly differed from that of 
vehicle-treated rats, and MK-801 coadministration influ-
enced amphetamine effects. Two-way ANOVA revealed effects 
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of treatment (F4,56  =  22.09, p  =  0.0001), time (F2,112  =  14.43, 
p  =  0.0001), and treatment × time interaction (F8,112  =  5.25, 
p = 0.0001). Tukey’s test showed that amphetamine-stimulated 
vocalizations developed sensitization with repeated treatment. 
Coadministration of MK-801 (0.1 mg/kg) suppressed ampheta-
mine-stimulated vocalizations only on the first administra-
tion day, while coadministration of MK-801 (0.2 or 0.5 mg/kg) 
elicited this effect at every time point considered (Figure  3C, 
Supplementary Table S2).
The locomotor activity of rats repeatedly treated with 
amphetamine (1 mg/kg) significantly differed from that of 
vehicle-treated rats, and MK-801 coadministration influenced 
amphetamine effects. Two-way ANOVA revealed effects of treat-
ment (F4,56 = 140.16, p = 0.0001), time (F2,112 = 33.78, p = 0.0001), and 
treatment × time interaction (F8,112 = 16.08, p = 0.0001). Tukey’s 
test showed a further increase in locomotor activity in rats 
coadministered MK-801 (0.2 or 0.5 mg/kg). This effect was pre-
sent at every time point considered, and developed sensitization 
(Figure 3D, Supplementary Table S2).
The challenge with amphetamine (1 mg/kg) stimulated 
50 kHz USV emissions significantly different from the vehicle 
challenge, and previous MK-801 coadministration influenced 
Figure 3. Changes in the emission of 50 kHz ultrasonic vocalizations (USVs) and in locomotor activity induced by repeated treatment with MK-801 (MK, 0.1–
0.5 mg/kg, i.p.), or amphetamine (AMPH, 1 or 2 mg/kg, i.p.), administered alone or in combination with MK-801, and by subsequent challenge with either MK-801 
or amphetamine. Upper panels: (A) emission of 50 kHz USVs and (B) locomotor activity in rats repeatedly treated and challenged with MK-801 (0.1–0.5 mg/kg). 
Middle panels: (C) emission of 50 kHz USVs and (D) locomotor activity in rats repeatedly treated with amphetamine (1 mg/kg, i.p.), alone or in combination with 
MK-801 (0.1–0.5 mg/kg), and challenged with amphetamine (1 mg/kg, i.p.). Lower panels: (E) emission of 50 kHz USVs and (F) locomotor activity in rats repeatedly 
treated with amphetamine (2 mg/kg, i.p.), alone or in combination with MK-801 (0.1–0.5 mg/kg), and challenged with amphetamine (2 mg/kg, i.p.). Recording of 
USVs and locomotor activity lasted 30 min. Filled black symbols indicate p < 0.05 compared with vehicle (VEH)-treated rats. *p < 0.05 compared with the first 
drug administration within each experimental group. #p < 0.05 compared with the first administration of the corresponding dose of MK-801. §p < 0.05 compared 
with the first administration of amphetamine (1 mg/kg, i.p.). $p < 0.05 compared with the first administration of amphetamine (2 mg/kg, i.p.). VEH, n = 12; MK 
0.1, n = 9; MK 0.2, n = 11; MK 0.5, n = 8; AMPH 1, n = 22; AMPH 1 + MK 0.1, n = 7; AMPH 1 + MK 0.2, n = 12; AMPH 1 + MK 0.5, n = 8; AMPH 2, n = 15; AMPH 1 + MK 
(0.1–0.5), n = 8.
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this effect (one-way ANOVA, F4,56 = 21.39, p = 0.0001). Tukey’s test 
revealed that the amphetamine challenge stimulated higher 
vocalization than the vehicle challenge in rats pretreated with 
either amphetamine or amphetamine + MK-801 (0.1–0.5 mg/
kg). Moreover, t-test comparisons revealed that the ampheta-
mine challenge elicited higher vocalization compared with 
the first amphetamine administration in rats pretreated with 
either amphetamine (t = 5.27, df = 42, p = 0.0001) or ampheta-
mine + MK-801 (0.1 mg/kg; t = 3.59, df = 27, p = 0.001; Figure 3C, 
Supplementary Table S2).
The challenge with amphetamine (1 mg/kg) stimulated loco-
motor activity in a fashion significantly different from the vehi-
cle challenge, and previous MK-801 coadministration influenced 
this effect (one-way ANOVA, F4,56 = 14.02, p = 0.0001). Tukey’s test 
showed that the amphetamine challenge stimulated higher 
locomotor activity than the vehicle challenge in rats pretreated 
with either amphetamine or amphetamine + MK-801 (0.1 or 
0.2 mg/kg). Moreover, t-test comparisons revealed that the 
amphetamine challenge elicited higher locomotor activity com-
pared with the first amphetamine administration in rats pre-
treated with either amphetamine (t = 4.57, df = 42, p = 0.0001) 
or amphetamine + MK-801 (0.1 mg/kg) (t = 2.19, df = 27, p = 0.04; 
Figure 3D, Supplementary Table S2).
Amphetamine (2 mg/kg) 
Emissions of 50 kHz USVs by rats repeatedly treated with 
amphetamine (2 mg/kg) significantly differed from those dis-
played by vehicle-treated rats, and MK-801 coadministration 
influenced amphetamine effects. Two-way ANOVA revealed 
effects of treatment (F4,46 = 28.49, p = 0.0001), time (F2,92 = 21.05, 
p  =  0.0001), and treatment × time interaction (F8,92  =  3.34, 
p = 0.002). Tukey’s test showed that amphetamine-stimulated 
vocalizations developed sensitization with repeated treatment. 
Coadministration of MK-801 (0.2 mg/kg) suppressed ampheta-
mine-stimulated vocalization on the first and fifth adminis-
tration days, while coadministration of MK-801 (0.5 mg/kg) 
elicited this effect at every time point considered (Figure  3E, 
Supplementary Table S3).
The locomotor activity of rats repeatedly treated with 
amphetamine (2 mg/kg) significantly differed from that of 
vehicle-treated rats, and MK-801 coadministration influenced 
amphetamine effects. Two-way ANOVA revealed effects of treat-
ment (F4,46 = 143.95, p = 0.0001), time (F2,92 = 32.76, p = 0.0001), and 
treatment × time interaction (F8,92 = 8.76, p = 0.0001). Tukey’s test 
showed that coadministration of MK-801 (0.5 mg/kg) potentiated 
amphetamine-stimulated locomotion at every time point con-
sidered (Figure 3F, Supplementary Table S3).
The challenge with amphetamine (2 mg/kg) stimulated 
50 kHz USV emissions significantly different from the vehicle 
challenge, and previous MK-801 coadministration influenced 
this effect (one-way ANOVA, F4,46 = 18.80, p = 0.0001). Tukey’s test 
showed that the amphetamine challenge stimulated higher 
vocalization than the vehicle challenge in rats pretreated with 
either amphetamine or amphetamine + MK-801 (0.1–0.5 mg/kg; 
Figure 3E, Supplementary Table S3).
The challenge with amphetamine (2 mg/kg) stimulated loco-
motor activity in a fashion significantly different from the vehi-
cle challenge, and previous MK-801 coadministration influenced 
this effect (one-way ANOVA, F4,46 = 31.75, p = 0.0001). Tukey’s test 
revealed that the amphetamine challenge induced higher loco-
motor activity than the vehicle challenge in rats pretreated with 
either amphetamine or amphetamine + MK-801 (0.1–0.5 mg/kg). 
Moreover, t-test comparisons revealed that the amphetamine 
challenge stimulated higher locomotor activity compared with 
the first amphetamine administration in amphetamine-pre-
treated rats (t = 3.23, df = 28, p = 0.004; Figure 3F, Supplementary 
Table S3).
Emission of Conditioned 50 kHz USVs During Test-
Cage Re-Exposure Under Drug-Free Conditions
MK-801
When re-exposed to the test cage, rats previously treated 
with MK-801 (0.1–0.5 mg/kg) displayed similar 50 kHz USV 
emissions compared with vehicle-pretreated rats (Figure  4A; 
Supplementary Table S1).
Amphetamine and Amphetamine + MK-801
Amphetamine (1 mg/kg) 
When re-exposed to the test cage, rats previously treated 
with amphetamine (1 mg/kg) displayed 50 kHz USV emissions 
significantly different from those in vehicle-pretreated rats, 
and previous MK-801 coadministration influenced this effect 
(one-way ANOVA, F4,56 = 14.27, p = 0.0002). Tukey’s test showed 
that amphetamine-pretreated rats vocalized more than vehi-
cle-pretreated rats, while rats pretreated with amphetamine 
+ MK-801 (0.1–0.5 mg/kg) did not (Figure  4B, Supplementary 
Table S2).
Amphetamine (2 mg/kg)
When re-exposed to the test cage, rats previously treated 
with amphetamine (2 mg/kg) exhibited 50 kHz USV emissions 
significantly different from those in vehicle-pretreated rats, 
and previous MK-801 coadministration influenced this effect 
(one-way ANOVA, F4,46 = 6.78, p = 0.0002). Tukey’s test showed 
that amphetamine-pretreated rats vocalized more than vehi-
cle-pretreated rats, while rats pretreated with amphetamine 
+ MK-801 (0.1–0.5 mg/kg) did not (Figure  4C, Supplementary 
Table S3).
Spontaneous Alternation
Acute pharmacological treatment significantly modified spon-
taneous alternation compared with drug-free conditions (one-
way ANOVA, F10,66 = 3.92, p = 0.0001). Tukey’s test showed reduced 
spontaneous alternation in rats treated with MK-801 (0.5 mg/kg) 
and amphetamine (1 mg/kg) + MK-801 (0.2 mg/kg; Figure 5).
Immunofluorescence
The drug challenge modified the levels of Zif-268 in a fashion 
significantly different from the vehicle challenge. One-way 
ANOVA revealed effect of treatment in the NAc shell (F3,19 = 19.26, 
p = 0.0001), NAc core (F3,19 = 5.74, p = 0.006), mPFC (F3,19 = 8.17, 
p = 0.001), and DLS (F3,19 = 9.64, p = 0.0004). Tukey’s test showed 
higher levels of Zif-268 in the NAc shell and core, mPFC, and DLS 
of the AMPH/AMPH group, compared with the VEH/VEH and the 
MK-801/MK-801 groups. Higher levels of Zif-268 were also found 
in the NAc shell, mPFC, and DLS of the AMPH/AMPH group com-
pared with the AMPH + MK-801/AMPH group (Figure 6A–D).
Summary of Major Findings
The major findings of this study can be summarized as follows.
Coadministration of MK-801 suppressed the induction 
and expression of 50 kHz USV sensitization in rats repeatedly 
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treated with amphetamine. However, this effect could be 
observed only at doses of MK-801 that themselves suppressed 
vocalization.
Previous coadministration of MK-801 suppressed the emis-
sion of conditioned 50 kHz USVs by amphetamine-treated rats 
re-exposed to the previously drug-paired environment. This 
effect occurred even at a low dose of MK-801 that did not alter 
the vocalization recorded immediately after amphetamine 
administration.
MK-801 elicited divergent effects on USVs and locomotor 
activity stimulated by amphetamine.
The effects of MK-801 on amphetamine-stimulated 50 kHz 
USVs were paired with modifications in spontaneous alterna-
tion and Zif-268 expression in different brain regions.
Discussion
Previous studies have demonstrated that the activation of glu-
tamate transmission has a permissive influence on rat 50 kHz 
USVs. Intracerebral administration of glutamate stimulates 
50 kHz USVs (Fu and Brudzynski, 1994), and the NMDA recep-
tor partial agonist D-cycloserine promotes vocalization in 
Figure 4. Emission of conditioned 50 kHz ultrasonic vocalizations (USVs) by rats previously treated in the test cage with MK-801 (MK, 0.1–0.5 mg/kg, i.p.), amphetamine 
(AMPH, 1 or 2 mg/kg, i.p.), or their combination. (A) Emission of conditioned 50 kHz USVs by rats pretreated with MK-801 (0.1–0.5 mg/kg, i.p.) alone. (B) Emission of condi-
tioned 50 kHz USVs by rats pretreated with amphetamine (1 mg/kg, i.p.), alone or in combination with MK-801 (0.1–0.5 mg/kg). (C) Emission of conditioned 50 kHz USVs 
by rats pretreated with amphetamine (2 mg/kg, i.p.), alone or in combination with MK-801 (0.1–0.5 mg/kg, i.p.). USV recordings were performed in drug-free conditions 
immediately after the re-exposure of rats to the test cage and before the drug challenge, and lasted 10 min. *p < 0.05 compared with vehicle (VEH)-pretreated rats and 
rats pretreated with amphetamine in combination with MK-801 (AMPH 1 or 2 mg/ kg, i.p. + MK, 0.1-0.5 mg/kg, i.p.). VEH, n = 12; MK 0.1, n = 9; MK 0.2, n = 11; MK 0.5 n = 8; 
AMPH 1, n = 22; AMPH 1 + MK 0.1, n = 7; AMPH 1 + MK 0.2, n = 12; AMPH 1 + MK 0.5, n = 8; AMPH 2, n = 15; AMPH 1 + MK (0.1–0.5), n = 8.
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rats selected for low levels of tickling-stimulated 50 kHz USVs 
(Moskal et  al., 2011). Conversely, the NMDA receptor antago-
nists MK-801 and phencyclidine suppress tickling-stimulated 
50 kHz USVs (Panksepp and Burgdorf, 2000; Boulay et al., 2013). 
The present study demonstrates, for the first time, that the 
permissive influence of glutamate transmission extends to the 
vocalizations stimulated by a drug with abuse properties such 
as amphetamine.
Besides the findings on 50 kHz USVs, this study confirmed 
that MK-801 coadministration suppresses locomotor sensitiza-
tion in rodents repeatedly treated with amphetamine (reviewed 
in Wolf, 1998). Locomotor sensitization is considered to be a cor-
relate of the changes in the motivational properties of addic-
tive drugs with repeated administration (Robinson and Berridge, 
2001), and recent studies have suggested that sensitization in 
drug-stimulated 50 kHz USVs could have similar significance 
(Ahrens et al., 2009; Mu et al., 2009; Simola and Morelli, 2015). In 
this regard, it is noteworthy that neuroplastic changes in brain 
regions involved in motivational processes (e.g. NAc, mPFC) are 
thought to underlie drug-induced sensitization (Vanderschuren 
and Kalivas, 2000), and that NMDA receptors are critically 
involved in neuroplasticity (Lau and Zukin, 2007). However, this 
study found that NMDA receptor antagonism elicited opposite 
effects on amphetamine-stimulated locomotor activity and 
50 kHz USV emissions. Moreover, this study found that previous 
MK-801 coadministration prevented the emission of conditioned 
50 kHz USVs by amphetamine-treated rats upon re-exposure to 
the drug-paired environment. Interestingly, this effect could be 
observed even in rats administered MK-801 at a dose that was 
ineffective in sensitization of amphetamine-stimulated 50 kHz 
USVs, suggesting that the NMDA receptor antagonism is more 
effective on conditioned vocalizations.
Previous investigations have demonstrated that con-
comitant NMDA receptor antagonism prevents the molecu-
lar changes that accompany the behavioral sensitization 
produced by amphetamine (Wolf et  al., 1994; Wolf, 1998). 
These findings could explain why MK-801 suppressed both 
the induction and expression of 50 kHz USV sensitization in 
amphetamine-treated rats. Moreover, these earlier findings 
would agree with the immunofluorescence results of this 
study, showing that rats previously coadministered MK-801 
at a dose (0.2 mg/kg) that prevented 50 kHz USV sensitiza-
tion displayed reduced levels of Zif-268 following ampheta-
mine challenge. Notably, this effect was observed in the NAc 
shell, which plays a crucial role in 50 kHz USV emissions. 
This would suggest that previous NMDA receptor antagonism 
may cause a persistent reduced sensitivity of NAc shell neu-
rons to the effects of amphetamine, which could explain the 
lower effects of the amphetamine challenge on 50 kHz USV 
emissions in rats previously administered MK-801. However, 
lower levels of Zif-268 were also observed in the DLS and 
mPFC, which are major targets of the neuroplastic changes 
induced by repeated treatment with addictive substances 
(Vanderschuren and Kalivas, 2000; Robbins et al., 2008). This, 
in turn, would suggest that regions other than the NAc shell 
might participate in the effects of NMDA receptor antagonism 
on amphetamine-stimulated 50 kHz USVs. Alternatively, it 
is possible that changes in neuronal activity in the DLS and 
mPFC may influence the long-term changes in the respon-
siveness of NAc shell neurons to amphetamine (see King 
et al., 1997). However, the proposed influence of NMDA recep-
tor antagonism on amphetamine-induced neuroplasticity 
seems in apparent contrast with the scarce emission of con-
ditioned 50 kHz USVs by the rats pretreated with ampheta-
mine and MK-801 (0.1 mg/kg), a dose that did not attenuate 
sensitization in amphetamine-stimulated 50 kHz USVs. One 
hypothesis that could explain these discrepant results is that 
NMDA receptor antagonism might modulate amphetamine-
induced neuroplasticity in a way that selectively affects con-
ditioned vocalizations. It is noteworthy that the 0.1 mg/kg 
dose of MK-801 has been reported to suppress the behavioral 
responses mediated by the activation of D1 receptors (Morelli 
and Di Chiara, 1990; Kreipke and Walker, 2004), and that these 
receptors are critically involved in drug conditioning (Di 
Chiara et al., 2004). However, other mechanisms besides the 
opposite NMDA-D1 receptor interactions could underlie the 
effects of MK-801 on conditioned 50 kHz USV emissions by 
amphetamine-treated rats.
Figure 5. Effects of acute treatment with MK-801 (MK, 0.1–0.5 mg/kg, i.p.), amphetamine (AMPH, 1 mg/kg, i.p.), and amphetamine (1 mg/kg, i.p.) in combination with 
MK-801 (0.1 or 0.2 mg/kg, i.p.) on rats’ spontaneous alternation in a Y maze. Spontaneous alternation is reported as a percentage of alternation triplets calculated over 
the total number of triplets, the latter corresponding to the number of arm entries minus two. *p < 0.05 compared with spontaneous alternation evaluated in drug-free 
conditions. Drug free, n = 7; acute treatment, n = 7.
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Figure 6. Effects of challenge with MK-801 (0.2 mg/kg, i.p.) or amphetamine (1 mg/kg, i.p.) administered 7 days after repeated treatment discontinuation on 
the levels of Zif-268 in the nucleus accumbens (NAc) shell and core, medial prefrontal cortex (mPFC), and dorsolateral striatum (DLS). The figure reports rep-
resentative high-resolution images (×100) immunostained for Zif-268 and histograms for NAc (A) shell and (B) core, (C) mPFC, and (D) DLS. Rats challenged 
with MK-801 were pretreated with MK-801 (0.2 mg/kg, i.p.). Rats challenged with amphetamine (AMPH) were pretreated with either amphetamine (1 mg/kg, 
i.p.) alone (AMPH/AMPH) or amphetamine (1 mg/kg, i.p.) in combination with MK-801 (0.2 mg/kg, i.p.; AMPH+MK-801/AMPH). The graphs show the percentage 
of Zif-268-positive nuclei compared with rats pretreated with vehicle (VEH) and challenged with vehicle (VEH/VEH). *p < 0.05 compared with VEH/VEH rats. 
^p < 0.05 compared with MK-801/MK-801 rats. #p < 0.05 compared with AMPH+MK-801/AMPH rats. Scale bar, 100 μm. VEH/VEH, MK-801/MK-801, AMPH/AMPH, 
AMPH+MK-801/AMPH, n = 6.
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Antagonism of NMDA receptors induces amnesia in rats 
(Zhang et al., 2001; Tronel and Sara, 2003) and, in line with this, 
MK-801 was here found to impair rats’ spontaneous alterna-
tion. This finding appears relevant to amphetamine-stimulated 
50 kHz USVs, since NMDA receptor antagonism can interfere 
with Pavlovian conditioning and long-lasting memories asso-
ciated with the administration of addictive drugs (Sadler et al., 
2007; Milton et al., 2012). However, rats coadministered amphet-
amine with the lower dose of MK-801 (0.1 mg/kg) in this study, 
while displaying negligible conditioned vocalization, exhibited 
no significant changes in spontaneous alternation. In this regard, 
it could be hypothesized that the emission of conditioned vocal-
izations is sensitive to submaximal amnesic deficits induced 
by NMDA receptor antagonism. Interestingly, this view would 
agree with earlier evidence showing that spontaneous alterna-
tion in a Y maze is relatively unaffected by subtle amnesic defi-
cits (Simola et al., 2008). Alternatively, it is possible that NMDA 
receptor antagonism might have impaired reconsolidation of 
memory for environmental cues previously associated with 
amphetamine, an effect that has been reported after the admin-
istration of 0.1 mg/kg MK-801 (Sadler et al., 2007). Therefore, the 
modifications involving 50 kHz USVs in amphetamine-treated 
rats observed here could depend on a dual modulatory effect 
of NMDA receptor blockade on neuroplastic changes and long-
term memories associated with amphetamine administration.
An additional issue to consider regarding the involvement of 
learning in the present results is that MK-801 has been suggested 
to promote state-dependent learning (defined in Sripada et al., 
2001) when coadministered with psychostimulants (Carlezon 
et  al., 1995; Ranaldi et  al., 2000). Accordingly, state-dependent 
learning has been proposed to underlie the lack of behavioral 
sensitization in rats coadministered amphetamine and MK-801. 
However, others have challenged this hypothesis (Li and Wolf, 
1999; Sripada et al., 2001), and similar considerations seem to 
apply to the present results. Regarding the vocalizations emitted 
immediately after amphetamine administration, it is notewor-
thy that while rats coadministered amphetamine (1 mg/kg) and 
MK-801 (0.1 mg/kg) developed 50 kHz USV sensitization during 
repeated treatment, they also displayed sensitized vocalization 
following the amphetamine challenge in the absence of MK-801. 
Nevertheless, it could be hypothesized that state-dependent 
learning may underlie the scarce conditioned vocalization by 
rats pretreated with amphetamine and MK-801. However, the 
present study always evaluated conditioned 50 kHz USVs in 
drug-free conditions, and rats treated with amphetamine alone 
exhibited a strong conditioned vocalization. Together, these 
considerations suggest that state-dependent learning is not 
involved in the results of this study.
In addition to the mechanisms discussed above, it is pos-
sible that other effects of MK-801 on rats’ behavior could have 
contributed to the present results. This study observed a sig-
nificant attenuation of amphetamine-stimulated 50 kHz USVs 
during repeated treatment only in rats coadministered doses of 
MK-801 that suppressed vocalization. Therefore, the 50 kHz USV 
emissions during repeated treatment by rats coadministered 
amphetamine and MK-801 could simply represent the net effect 
of these drugs on vocalization. Moreover, the present study has 
found that MK-801 elicits dose-dependent opposite effects on 
locomotor activity and 50 kHz USV sensitization induced by 
amphetamine. Interestingly, these effects were not observed 
following the amphetamine challenge (in the absence of 
MK-801), which stimulated both locomotor activity and 50 kHz 
USV emissions, though neither one sensitized in the same rats. 
These findings would suggest that other effects of MK-801 on 
rats’ behavior (e.g. suppression of vocalization, excessive motor 
stimulation) could interfere with the vocalization evaluated 
immediately after amphetamine and MK-801 coadministration. 
Therefore, this study suggests that pharmacological investiga-
tions of the role of non-dopaminergic transmitters in 50 kHz USV 
emissions should cautiously consider the behavioral effects of 
drugs targeting these transmitters that could interfere with the 
results observed.
In conclusion, this study provides the first demonstration 
that glutamate transmission mediated by NMDA receptors par-
ticipates in the effects of amphetamine on 50 kHz USVs. In light 
of the crucial role of NMDA receptors in drug-induced behavioral 
sensitization, these findings further validate the use of 50 kHz 
USVs in the study of the motivational properties of ampheta-
mine. Moreover, the present results agree with earlier data on 
the significance of 50 kHz USVs in the study of addictive drugs. 
First, this study provides further evidence that the acute and 
long-term effects of drugs on 50 kHz USVs may differ (Simola 
et  al., 2014), and that vocalizations emitted immediately after 
drug administration and conditioned vocalizations may have a 
different significance with regard to the motivational properties 
of drugs (Simola and Morelli, 2015). Second, this study strength-
ens the idea that the significance of locomotor activity may not 
completely overlap that of 50 kHz USV emissions, with regard 
to the changes in the motivational properties of amphetamine 
after repeated experience (Taracha et  al., 2014; Simola and 
Morelli, 2015).
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